Physiomics PLC Appointment of Independent Non-Executive Director (3065G)

TIDMPYC

RNS Number : 3065G

Physiomics PLC

29 March 2022

29 March 2022

Physiomics plc

("Physiomics") or ("the Company")

Physiomics appoints new Independent Non-Executive Director

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Dr Tim Corn will join the Company's board as an Independent Non-Executive Director from 1 April 2022.

Dr Tim Corn qualified in medicine at King's College Hospital and, after becoming honorary Consultant and Senior Lecturer, joined the pharmaceutical industry in 1983. He has held senior positions in both big and small pharma as well as at the MHRA and became Chief Medical Officer ("CMO") of several small but highly successful venture-backed companies, such as EUSA Pharma and Zeneus Pharma. He has played a key role in more than twenty regulatory approvals in the USA and Europe, is the author of more than forty scientific publications, and was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Tim previously served as Chairman and Non-Executive Director on the Board of Reneuron plc (AIM: RENE), and currently serves as a Trustee of Nerve Tumours UK, and as CMO of Nodenza Inc.

Dr Jim Millen, CEO, commented : "My colleagues and I are delighted to have been able to attract someone of Tim's calibre and experience to our board of directors. Tim is perfectly positioned to advise us on issues relating to our core consulting business and has already provided valuable input into the discussion of strategic initiatives through his participation in our advisory board last year. I'd like to personally welcome Tim to the Company and look forward to working with him going forwards."

Further information on Tim Corn's appointment :

The following details in relation to the appointment of Dr Timothy ("Tim") Corn are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules:

Timothy Henry Corn (aged 70 ) has held the following directorships in the past five years.

 
                                        Past Directorships / Partnerships 
 Current Directorships / Partnerships    (last five years) 
 Reneuron Group plc                     Neurocentrx Pharma Limited 
                                       ---------------------------------- 
 The Neurofibromatosis Association      Circassia Group PLC 
                                       ---------------------------------- 
 Zenios Bioscience LLP                  HERA 
                                       ---------------------------------- 
 Aesclepius Consulting Ltd 
                                       ---------------------------------- 
 Carter Communications Ltd 
                                       ---------------------------------- 
 Tots with Tumours Ltd 
                                       ---------------------------------- 
 Kids with Tumours Ltd 
                                       ---------------------------------- 
 Children with Tumours Ltd 
                                       ---------------------------------- 
 

There is no further information to be disclosed in relation to Tim Corn's appointment pursuant to AIM Rule 17 or Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFEDVRITFIF

(END) Dow Jones Newswires

March 29, 2022 02:01 ET (06:01 GMT)